Dosimetry and optimization of in vivo targeting with radiolabeled antisense oligodeoxynucleotides: oligonucleotide radiotherapy.
Kairemo
K J
KJ
Department of Clinical Chemistry, Norwegian University of Science and Technology, Trondheim, Norway.
Jekunen
A P
AP
Tenhunen
M
M
D000818:Animals; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000532:radiotherapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011829:Radiation Dosage; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013462:Sulfur Radioisotopes / Q000627:therapeutic use; D013873:Thionucleotides / Q000627:therapeutic use*
D020319:Oligodeoxyribonucleotides, Antisense; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013462:Sulfur Radioisotopes; D013873:Thionucleotides